Hamlet BioPharma AB (publ)

NGM:HAMLET B 株式レポート

時価総額：SEK 439.5m

Hamlet BioPharma マネジメント

マネジメント 基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Petter Lindqvist

最高経営責任者

n/a

報酬総額

CEO給与比率n/a
CEO在任期間1.1yrs
CEOの所有権n/a
経営陣の平均在職期間データなし
取締役会の平均在任期間データなし

経営陣の近況

Recent updates

Is Hamlet Pharma (NGM:HAMLET B) In A Good Position To Invest In Growth?

Jul 04
Is Hamlet Pharma (NGM:HAMLET B) In A Good Position To Invest In Growth?

Here's Why We're Watching Hamlet Pharma's (NGM:HAMLET B) Cash Burn Situation

Mar 04
Here's Why We're Watching Hamlet Pharma's (NGM:HAMLET B) Cash Burn Situation

We Think Hamlet Pharma (NGM:HAMLET B) Can Afford To Drive Business Growth

Nov 10
We Think Hamlet Pharma (NGM:HAMLET B) Can Afford To Drive Business Growth

We Think Hamlet Pharma (NGM:HAMLET B) Can Easily Afford To Drive Business Growth

Jun 17
We Think Hamlet Pharma (NGM:HAMLET B) Can Easily Afford To Drive Business Growth

Companies Like Hamlet Pharma (NGM:HAMLET B) Are In A Position To Invest In Growth

Oct 12
Companies Like Hamlet Pharma (NGM:HAMLET B) Are In A Position To Invest In Growth

Will Hamlet Pharma (NGM:HAMLET B) Spend Its Cash Wisely?

Mar 17
Will Hamlet Pharma (NGM:HAMLET B) Spend Its Cash Wisely?

CEO（最高経営責任者

Petter Lindqvist

1.1yrs

在職期間

Mr. Petter Segelman Lindqvist serves as Chief Executive Officer of Isofol Medical AB (publ) since January 09, 2024. He is Chief Executive Officer of Hamlet BioPharma AB (publ) (formerly known as Hamlet Pha...